4.2 Deemed Accreditation Organizations (CAP, The Joint Commission, COLA, ISO 15189)
Key Takeaways
- CMS may recognize an accreditation organization whose requirements meet or exceed CLIA, but CMS retains oversight through validation and complaint surveys.
- CAP uses peer inspection on a two-year cycle; U.S. and Canadian laboratories generally receive no more than 14 calendar days’ notice and conduct a self-inspection in the intervening year.
- CAP deficiency responses are due within 30 calendar days; Phase II responses require supporting evidence, while the checklist item determines the phase.
- For regulated analytes, CLIA PT generally uses three events per year and laboratories test PT samples like patient specimens without interlaboratory communication before the reporting deadline.
- Unsuccessful PT performance requires investigation and correction, but CMS enforcement is case-specific; current guidance does not impose one automatic six-month cessation rule for every initial unsuccessful event.
Deemed Accreditation Organizations and Proficiency Testing
CLIA deeming authority
CMS may approve a private accreditation organization when its requirements and enforcement are equal to or more stringent than CLIA. A laboratory accredited by an approved organization receives a Certificate of Accreditation from CMS and is ordinarily surveyed by that organization instead of the State Survey Agency. Deemed status does not eliminate federal oversight. CMS or a State Survey Agency may conduct validation or complaint surveys and may act on condition-level noncompliance.
Laboratory leaders should distinguish four sources of requirements: federal CLIA law and regulation; CMS interpretive guidance and survey procedures; the chosen accreditor's current standards and checklist; and state or local rules that may be more stringent. When sources differ, comply with every applicable requirement.
Comparing accreditation approaches
| Program | Characteristic approach | Management focus |
|---|---|---|
| CAP Laboratory Accreditation Program | Peer inspection with detailed laboratory and discipline checklists | Evidence that each checklist requirement is implemented and effective |
| The Joint Commission laboratory program | Tracer-oriented review integrated with patient-care systems | Handoffs, identification, communication, and system-level risk |
| COLA | Survey and education oriented toward laboratories including physician-office settings | Sustainable compliance and corrective improvement |
| AABB | Specialized standards for blood, transfusion, cellular therapy, and biotherapies | Donor/recipient safety, traceability, and product controls |
| ISO 15189 accreditation | Process and competence assessment against an international QMS standard | Risk, impartiality, competence, audit, and continual improvement |
ISO 15189 is a standard; the actual accrediting body and scope must be identified rather than treating “ISO” as a regulator.
CAP inspection cycle and preparation
CAP-accredited laboratories are inspected on a two-year cycle. CAP states that laboratories in the United States and Canada receive no more than 14 calendar days' notice of an inspection. During the intervening year the laboratory completes a self-inspection using the current checklists. Inspection timing or notice outside those jurisdictions may differ, so managers follow current CAP instructions.
Readiness is continuous. A useful evidence chain for any checklist item is a current approved procedure, routine performance records, competency or training evidence where relevant, review of exceptions and trends, and corrective action with effectiveness evidence when performance fails. Tracers and staff interviews should agree with the written procedure.
CAP deficiencies and responses
CAP checklist requirements are assigned Phase I or Phase II; the phase is attached to the cited checklist item, not improvised from an informal “minor versus serious” label. CAP requires a response to all deficiencies within 30 calendar days. A Phase I response describes corrective action. A Phase II response also supplies supporting documentation demonstrating compliance.
For either phase, define scope, correct immediate risk, identify causes, implement systemic action, and verify effectiveness. If patient results may be affected, conduct a documented look-back, decide whether reports require correction, and notify clinicians as required.
Tracer methodology
A tracer follows a patient, specimen, result, or process across handoffs. For a blood culture, it could examine the order, identifiers, collection antisepsis, transport, incubation, alerts, preliminary calls, susceptibility reporting, critical-result documentation, and stewardship follow-up. A tracer is valuable because a technically correct bench process can still fail at an interface.
Proficiency testing fundamentals
For CLIA-regulated analytes, laboratories enroll in a CMS-approved PT program. The usual design is three testing events per year with five challenges per regulated analyte per event, subject to current specialty rules. PT samples are tested like patient specimens by routine personnel using the routine method. Before the reporting deadline, the laboratory must not send PT material to another laboratory for testing or communicate results in a way that creates interlaboratory collaboration.
The laboratory director reviews PT results. For each unacceptable result, investigate transcription, specimen handling, reagent and calibration status, instrument function, peer-group assignment, calculations, and staff practice. Corrective action is documented even when the overall event remains satisfactory.
Unsatisfactory and unsuccessful performance
The precise scoring criteria and terminology are in 42 CFR Part 493 and current CMS guidance. A single unacceptable event may be unsatisfactory performance; repeated failures meeting the regulatory pattern are unsuccessful performance. The manager must classify performance for the specific analyte or subspecialty and act promptly.
Older summaries often state that every initial unsuccessful PT finding automatically causes a six-month testing suspension. Current CMS enforcement guidance is more nuanced. CMS may direct training or technical assistance after an initial unsuccessful performance. Sanctions or directed cessation depend on facts such as immediate jeopardy, failure to correct, and compliance history. There is no single enforcement response for every laboratory and every initial event.
PT referral
PT referral is distinct from poor analytical performance. Intentional referral or interlaboratory communication can trigger severe statutory consequences, but current law and CMS guidance contain defined enforcement paths and possible alternative sanctions in specified circumstances. The operational rule is simple: keep PT inside the laboratory's ordinary patient-testing workflow, document who performed it, prohibit pre-deadline result sharing, and escalate suspected referral immediately.
Survey response workflow
When an accreditor or CMS identifies a deficiency: protect patients and stop unsafe testing if necessary; preserve records and define scope; perform a patient-result look-back when indicated; correct immediate problems; identify systemic causes; submit the response by the required deadline with required evidence; and monitor effectiveness until sustained compliance is demonstrated.
Why may a State Survey Agency inspect a laboratory that holds a Certificate of Accreditation from a deemed organization?
A laboratory has initial unsuccessful PT performance for one regulated analyte. Which response best reflects current CMS guidance?
Which statement correctly describes a CAP deficiency response?